CHAPEL HILL, N.C.--(BUSINESS WIRE)--April 20, 2006--POZEN Inc. (NASDAQ: POZN - News) announced today that it has completed a Special Protocol Assessment (SPA) and reached agreement with the U.S. Food and Drug Administration (FDA) on the design of its pivotal trials for PN 200. PN 200 is a product candidate for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk for developing NSAID-associated gastric ulcers. The SPA is a process by which the FDA provides evaluation and guidance on proposed protocols for clinical trials.
